Philip R. Dormitzer, M.D., Ph.D

Pfizer

Vice President and Chief Scientific Officer, Viral Vaccines

Philip R. Dormitzer, M.D., Ph.D., is Vice President and Chief Scientific Officer, Viral Vaccines, Pfizer, where he leads Pfizer’s viral vaccines research and development programs, which include the Pfizer-BioNTech RNA-based COVID-19 pandemic vaccine and influenza vaccine collaborations. The COVID-19 vaccine has been authorized for emergency use, and mass vaccination campaigns are in progress around the world. A prefusion F-based RSV vaccine to protect infants through maternal immunization has been advanced from discovery to a global Phase III clinical trial in pregnant women. A cytomegalovirus vaccine candidate is in preclinical development.  

Before joining Pfizer, Dr. Dormitzer held positions at Novartis Vaccines that included Head of US Research. He was the founding member of the Novartis Viral Vaccine Research Center in Cambridge, Massachusetts. In 2009, his research team supported the development and licensure of three H1N1v influenza pandemic vaccines in what remains the most rapid vaccine response in history. In 2013, his team responded to the H7N9 influenza outbreak by supplying the US pre-pandemic stockpile with a vaccine generated from a synthesized virus.

Before joining industry, Dr. Dormitzer was an Assistant Professor of Pediatrics at Harvard Medical School and led a structural virology laboratory, which, with collaborators, determined the structures of the rotavirus neutralization antigens.  He graduated summa cum laude in anthropology from Harvard College, conducted paleontological research in Pakistan, and studied the Efe Pygmies in Zaire. He obtained a Ph.D. in Cancer Biology and an M.D. at Stanford University, completed Internal Medicine training at Massachusetts General Hospital, and completed the Harvard Infectious Diseases Program clinical fellowship.